|Bid||86.43 x 900|
|Ask||86.76 x 800|
|Day's Range||85.89 - 86.81|
|52 Week Range||73.54 - 95.00|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||17.81|
|Forward Dividend & Yield||2.83 (3.30%)|
|1y Target Est||101.00|
Sanofi has invested $1.5 billion into expanding over the last five years as it competes with companies like new CEO Paul Hudson’s former company Novartis Corp.
Moody's Investors Service ("Moody's") has today assigned a B3 rating to Rossini S.a r.l.'s (Rossini or "the company") proposed issuance of EUR650 million worth of senior secured floating rate notes. Rossini is an entity holding an indirect majority ownership in Recordati S.p.A. (Recordati).
Progenics Pharmaceuticals, Inc. Pushed Through Questionable Merger with Votes from Directors Who Had Resigned Progenics Agreed to Large Termination Fee in Possible Move to Trap Shareholders in Deal Corporate Governance Expert Finds Termination Fee, Lame Duck Director Votes “Troubling” Stock Trading Above Offer Price, Suggesting Shareholders Want A Kiss or Deal Scrapped By John […]
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
NEW YORK, Oct. 09, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
Novartis gained Food and Drug Administration approval Tuesday for an eye-disease treatment called Beovu that could undercut Regeneron Pharmaceuticals' blockbuster medicine, Eylea.
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly competitive market for eye problems among an ageing population. With the FDA's blessing, Beovu joins blockbuster predecessors Lucentis, which Novartis sells with Roche, and Eylea from both Bayer and Regeneron, in the AMD market.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Shares of Coherus Biosciences popped Friday on the possibility a rival biosimilar from Novartis may have been delayed. Coherus knocks off Amgen's branded drug, Neulasta, with a copycat drug.
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE/Nasdaq-listed biotech stocks hit 52-week highs on Oct. 1. Down In The Dumps (Biotech stocks hitting 52-week ...
Bausch Health Cos. Inc. shares slid more than 9% Tuesday, after the company said it is filing a lawsuit against Novartis AG unit Sandoz for infringing patents that protect the company’s blockbuster drug Xifaxan 550 mg tablets, a treatment for irritable bowel syndrome.